Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI

NCT01562678 on ClinicalTrials.gov · last registry update 2017-05-31

A small phase 4 — 28 participants, against a typical 75. The sponsor logged completion for May 2014. Primary outcome, as filed: Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Beth Israel Deaconess Medical Center
Sponsor type: Other
Enrollment: 28
Started: 2012-03
Primary completion: 2014-05 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization

Conditions studied

Diabetes · Effects of Liraglutide Administration on Brain Activity · Weight Loss · Hunger

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.